Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level903 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1) | active not recruiting | Phase 3 | 610 | Arcus Biosciences, Inc.INDUSTRY | 13 | Sep 29, 2026 | clinicaltrials |
| NCT04340141 | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | active not recruiting | Phase 3 | 358 | Alliance for Clinical Trials in OncologyOTHER | 2 |
| Sep 4, 2026 |
| clinicaltrials |
| NCT05836870 | Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer | active not recruiting | Phase 3 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06783140 | Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer(PLATINUM-CAN) | active not recruiting | Phase 2 / Phase 3 | 10 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT04927780 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer(PREOPANC-3) | active not recruiting | Phase 3 | 378 | Erasmus Medical CenterOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03899636 | A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer(DIRECT) | active not recruiting | Phase 3 | 528 | Angiodynamics, Inc.INDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | active not recruiting | Phase 2 / Phase 3 | 140 | Oslo University HospitalOTHER | 4 | Nov 20, 2024 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials